After Forming Double Bottom Pattern, Is Aclaris Therapeutics Inc (ACRS)’s Near-Term Analysis Negative?

September 17, 2017 - By Vivian Currie

The chart of Aclaris Therapeutics Inc (ACRS) shows a double bottom with $23.51 target or 9.00 % below today’s $25.83 share price. The 9 months chart pattern indicates high risk for the $774.81 million company. It was reported on Sep, 17 by Finviz.com. If the $23.51 price target is reached, the company will be worth $69.73M less. Double bottoms are rare but powerful chart patterns.

The stock decreased 2.31% or $0.61 on September 15, reaching $25.83. About 913,104 shares traded or 170.02% up from the average. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 25.57% since September 17, 2016 and is uptrending. It has outperformed by 8.87% the S&P500.

Analysts expect Aclaris Therapeutics Inc (NASDAQ:ACRS) to report $-0.89 EPS on November, 2.They anticipate $0.39 EPS change or 78.00 % from last quarter’s $-0.5 EPS. After having $-0.56 EPS previously, Aclaris Therapeutics Inc’s analysts see 58.93 % EPS growth.

Aclaris Therapeutics Inc (NASDAQ:ACRS) Ratings Coverage

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 13 analyst reports since November 2, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $3600 target in Monday, June 26 report. Jefferies initiated Aclaris Therapeutics Inc (NASDAQ:ACRS) rating on Monday, November 2. Jefferies has “Buy” rating and $20 target. The company was maintained on Monday, September 19 by Jefferies. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) has “Buy” rating given on Friday, July 28 by Jefferies. As per Wednesday, August 9, the company rating was maintained by Cantor Fitzgerald. Citigroup initiated the shares of ACRS in report on Monday, November 2 with “Buy” rating. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) earned “Market Perform” rating by JMP Securities on Friday, September 30. The rating was maintained by Jefferies with “Buy” on Friday, August 12. The company was initiated on Tuesday, November 29 by Leerink Swann. William Blair initiated the stock with “Outperform” rating in Monday, November 2 report.

More notable recent Aclaris Therapeutics Inc (NASDAQ:ACRS) news were published by: Seekingalpha.com which released: “Aclaris Therapeutics’ (ACRS) CEO Dr. Neal Walker on Q2 2017 Results – Earnings …” on August 11, 2017, also Globenewswire.com with their article: “Aclaris Therapeutics Announces Issuance of Two US Patents Covering JAK …” published on September 05, 2017, Globenewswire.com published: “Aclaris Therapeutics Reports First Quarter 2017 Financial Results” on May 09, 2017. More interesting news about Aclaris Therapeutics Inc (NASDAQ:ACRS) were released by: Globenewswire.com and their article: “Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical …” published on June 29, 2017 as well as Globenewswire.com‘s news article titled: “Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule …” with publication date: September 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.